Get the Stockscreener App
2.13
0.00%
0.00
Pre-market:
2.12
-0.010
-0.47%
Biodexa Pharmaceuticals Plc Adr stock is traded at $2.13, with a volume of 46,846.
It is up +0.00% in the last 24 hours and down -30.39% over the past month.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
See More
Previous Close:
$2.13
Open:
$2.17
24h Volume:
46,846
Relative Volume:
0.12
Market Cap:
$1.93M
Revenue:
$104.00K
Net Income/Loss:
$-8.39M
P/E Ratio:
-0.0205
EPS:
-103.9477
Net Cash Flow:
$-8.31M
1W Performance:
-7.79%
1M Performance:
-30.39%
6M Performance:
-80.72%
1Y Performance:
-94.96%
1-Day Range:
$1.97
$2.17
1-Week Range:
$1.97
$2.33
52-Week Range:
$1.97
$59.40
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Name
Biodexa Pharmaceuticals Plc Adr
Sector
Industry
Phone
-
Address
-
Compare BDRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
2.13 | 1.93M | 104.00K | -8.39M | -8.31M | -103.95 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-08-24 | Initiated | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Latest News
Biodexa Pharmaceuticals plc (BDRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Result of Annual General Meeting - Yahoo Finance UK
Biodexa prices $3.5 million offering with warrants - Investing.com
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants - Yahoo Finance UK
symbol__ Stock Quote Price and Forecast - CNN
Biodexa expands Serenta phase 3 trial into Canada By Investing.com - Investing.com India
Biodexa expands Serenta phase 3 trial into Canada - Investing.com
Biodexa Pharmaceuticals plc Sponsored ADR Actuals & Estimates (NASDAQ:BDRX) - TradingView
Postponement and Re-scheduling of Annual General Meeting - markets.businessinsider.com
BDRX News | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
BeOne Medicines Ltd.Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
BDRXBiodexa Pharmaceuticals Plc ADR Latest SEC Filings - Finviz
BDRX Stock Price, Quote & Chart | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Biodexa proposes share capital reorganization at June meeting - Investing.com UK
Biodexa issues letter to Shareholders - markets.businessinsider.com
Biodexa proposes share capital reorganization at June meeting By Investing.com - Investing.com Nigeria
Biodexa plans to shrink 373B shares without cutting ADS stakes - Stock Titan
BDRX Stock Jumps As Biodexa ADRs Lead Biotech Rally - StocksToTrade
BDRX Stock Jumps As ADR Momentum Attracts Active Traders - timothysykes.com
Biodexa Pharmaceuticals surges on pre-market trading - Intellectia AI
Inventory turnover of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
What Makes Haleon PLC Sponsored ADR (HLN) a New Buy Stock - Yahoo Finance
Net income before discontinued operations of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Book value per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Biodexa Pharmaceuticals plc Sponsored ADR Cash Flow – FWB:5MP2 - TradingView — Track All Markets
Net debt of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Basic earnings per share (basic EPS) of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Price to earnings ratio of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Who's Buying or Selling Biodexa Pharmaceuticals PLC (STU:5MP2) Stock Today? - GuruFocus
Biodexa Pharmaceuticals Plc: Shareholders Board Members Managers and Company Profile | US59564R8723 - marketscreener.com
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today? - Sahm
Why is Biodexa Pharmaceuticals (BDRX) stock skyrocketing today? - MSN
Biodexa partners with Syngene for MTX240 manufacturing By Investing.com - Investing.com Australia
171.7M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - Stock Titan
109.8M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - stocktitan.net
943.4M Ordinary Shares for Resale; Biodexa (NASDAQ: BDRX) resale filing - stocktitan.net
1.7018B shares for resale by holders — Biodexa (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADS for resale via equity line - Stock Titan
Biodexa’s eRapa Program: Global Expansion and European Gains - StocksToTrade
Biodexa partners with Syngene for MTX240 manufacturing - Investing.com
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies - ChartMill
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
No approved FAP drug: Biodexa opens global eRapa access - Stock Titan
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADSs for resale under equity line - Stock Titan
943.4M Ordinary Shares resale by selling holders (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (BDRX) flags going-concern doubts amid ongoing losses - Stock Titan
Biodexa (NASDAQ: BDRX) grows pipeline but warns on 2026 funding needs - stocktitan.net
Preliminary Results for the Year Ended 31 December 2025 - GlobeNewswire
Biodexa releases audited preliminary 2025 results for investors - Stock Titan
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
3.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):